The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and commercialization FDA to Convene Pharmacy Compounding Advisory Committee in July FDA moves toward easing restrictions on certain peptides BioPharma Dive The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York